If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones, and royalties on therapeutic product sales. In addition, Adimab reported the achievement of milestone payments from its ongoing collaborations with Eli Lilly and Kyowa Hakko Kirin. It relationship with Eli Lilly commenced in December 2010, and its partnership with Kyowa Hakko Kirin in January this year.